From the presentation. We do have a debt facility in place for the next acquisition but we are exploring other options.
From 25th Jan RNS on acquiring Dermatonics
"The Company is in advanced negotiations and diligence to acquire a second company in a similar sector, with total consideration of less than £2 million, where cash flow is positive and there are business synergies; this acquisition is currently expected to be completed in Q1 2024."
I hadn't realised 2nd acquisition was c. £2m. Perhaps target has changed. Was thinking more c. £0.5m?
"but recent work with dieticians at a speciality London obesity clinic has indicated SlimBiome® may have potential as an adjunct to treatment with Ozempic/Wegovy."
Mol, thanks again for your unstinting research and generosity in sharing. Although generally small studies in themselves, the consistent findings add weight to the research.
Agree, but will need news of something tangible to support. I am a LTH, but difficult decision time. Trade a few or hope for that news. My average is mid 50s so...
Thanks, Peter. I was wondering what readership might be. The interest in Opti shares has picked up. So would help if SOH could land some big news to capitalise!
Good summary mol. Thought they didn't dodge questions. Though we weren't told what f/c revenues are for 24 but assured they will be enough to avoid fundraise. Well for 12 months at least.